J&J’s Lung Cancer Treatment Is Successful In A Comparison Study With AstraZeneca’s Medication
According to a late-stage trial, Johnson & Johnson’s cancer treatment combination extended patients’ survival times with a certain non-small-cell lung cancer compared to AstraZeneca’s Tagrisso. On Thursday, J&J stated that it anticipates the combination will be used as a first-line therapy for patients with non-small-cell lung cancer (NSCLC) who have a specific mutation in the…









